Blossom Health, a New York-based telepsychiatry startup founded in 2024, has raised $20 million in combined seed and Series A funding to scale an AI-powered platform that pairs psychiatrists with clinical copilots and automated administrative support. The round was led by Headline, whose co-founder and managing partner Mathias Schilling is joining the company’s board. Village Global and TA Ventures returned from earlier rounds, with Operator Partners and Correlation Ventures joining as new institutional backers alongside angel investors including founders from General Catalyst, Flatiron Health, Sword Health, and Zip.
The company, founded by CEO John Zhao, is built around a specific premise: that the bottleneck in psychiatric care is not a shortage of clinical knowledge but a shortage of time. Psychiatrists in the United States spend roughly half their working hours on non-clinical tasks, including documentation, billing, insurance authorisation, and scheduling. Blossom’s platform automates much of this through a network of AI agents that handle billing, reception, care coordination, and medical scribing, while a separate set of clinical copilots assist with symptom evaluation, diagnosis refinement, and medication selection during patient encounters.
The scale of the problem
The psychiatric workforce shortage in the United States is severe and worsening. More than 122 million Americans live in federally designated mental health professional shortage areas, according to the Health Resources and Services Administration. The national psychiatrist-to-population ratio stands at one provider for every 5,058 residents. Roughly 60 per cent of practising psychiatrists are 55 or older, meaning a significant portion of the existing workforce will retire within the next decade. Wait times for an initial psychiatric appointment range from three weeks to six months depending on location, and in many rural counties there are no psychiatrists at all.
This gap has created a market. US digital health startups raised $14.2 billion in 2025, the highest total since 2022, with AI-powered companies accounting for 54 per cent of that funding. Within mental health specifically, Talkiatry, an in-network telepsychiatry platform, raised $210 million in February 2026. Spring Health, which uses AI for personalised treatment recommendations, is valued at $3.3 billion. Ambient clinical scribes, the category of AI that automatically generates notes from patient conversations, produced $600 million in revenue last year alone.
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
Blossom is small by comparison. The company says its tools are used by hundreds of clinicians treating more than 10,000 patients across multiple US states. Most patients are seen within 48 hours, with many receiving same-day appointments. Blossom accepts all major commercial insurers, including Optum UnitedHealthcare, Aetna, Cigna Evernorth, and Blue Cross Blue Shield, with average copays of around $22.
Copilot, not replacement
The “copilot” framing is deliberate and important. Blossom is not building a therapy chatbot. Its AI tools sit alongside licensed psychiatrists during clinical encounters, surfacing relevant information, helping evaluate symptoms against diagnostic criteria, and suggesting medication adjustments based on the patient’s history and current presentation. The psychiatrist retains clinical authority over every decision.
Between appointments, the platform uses AI agents to maintain contact with patients through text-based check-ins on sleep, mood, medication adherence, and other indicators. Fortune reported that in the case of postpartum depression, for example, the system follows up with conversational prompts that surface warning signs and prepare information for clinicians ahead of the next visit. This approach converts what has traditionally been episodic care, where a patient sees a psychiatrist for 15 minutes every few months and is otherwise unsupported, into something closer to continuous monitoring.
The clinical claims are plausible but early. Blossom says it has demonstrated the ability to stabilise mental health conditions and prevent progression toward more intensive care, but the company has not published peer-reviewed clinical evidence. At 10,000 patients, the dataset is meaningful for a company this young but far too small to draw population-level conclusions about clinical efficacy.
The Cerebral cautionary tale
Any startup operating at the intersection of AI, telepsychiatry, and controlled substance prescribing inherits the reputational burden of what came before. Cerebral, the telemental health company that raised $300 million at a $4.8 billion valuation in 2022, became the subject of a Department of Justice investigation into its prescribing practices for controlled substances and paid a $7 million settlement to the Federal Trade Commission over allegations of misleading cancellation policies and data sharing. The company’s rapid growth, which prioritised patient volume over clinical rigour, damaged trust across the sector.
Blossom’s architecture is different in important ways. It works through licensed psychiatrists rather than nurse practitioners prescribing independently, and its AI tools are positioned as decision support rather than decision-makers. But the fundamental tension remains: scaling psychiatric care through technology requires maintaining clinical quality at volumes that a traditional practice model was never designed to handle. The AI copilot must be good enough to genuinely assist clinicians without introducing errors that a time-pressed psychiatrist might not catch, particularly in medication selection, where psychiatric pharmacology is notoriously complex and highly individual.
The $20 million will fund expansion into additional US states, new insurance partnerships, clinician recruitment, and continued research and development. For a company founded less than two years ago, treating over 10,000 patients with in-network insurance coverage is a notable operational achievement. Whether the clinical copilot meaningfully improves outcomes, or simply makes it faster to deliver care at the same quality, is the question the next round of funding will need to answer.
